{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28dextrose%29&page=2",
    "query": {
      "intervention": "Placebo (dextrose)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 735,
    "total_pages": 74,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28dextrose%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28dextrose%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T11:20:51.849Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00673790",
      "title": "The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Nebivolol with concomitant losartan or lisinopril",
          "type": "DRUG"
        },
        {
          "name": "HCTZ with concomitant losartan or lisinopril",
          "type": "DRUG"
        },
        {
          "name": "Placebo with concomitant losartan or lisinopril",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 537,
      "start_date": "2008-05-15",
      "completion_date": "2010-07-09",
      "has_results": true,
      "last_update_posted_date": "2020-02-26",
      "last_synced_at": "2026-09-30T11:20:51.849Z",
      "location_count": 88,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00673790"
    },
    {
      "nct_id": "NCT03624985",
      "title": "The Effect of Perioperative Intravenous Lidocaine Infusion on Opioid Consumption After Lumbar Spine Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain, Postoperative",
        "Opioid Use"
      ],
      "interventions": [
        {
          "name": "Intravenous Lidocaine Infusion",
          "type": "DRUG"
        },
        {
          "name": "Placebo Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Vermont Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 61,
      "start_date": "2018-06-04",
      "completion_date": "2019-10-14",
      "has_results": false,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-09-30T11:20:51.849Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03624985"
    },
    {
      "nct_id": "NCT02953587",
      "title": "Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Oral Glucose Tolerance Test (OGTT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Human Ghrelin",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 70,
      "start_date": "2016-09",
      "completion_date": "2023-01-30",
      "has_results": false,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-09-30T11:20:51.849Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02953587"
    },
    {
      "nct_id": "NCT02561000",
      "title": "Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arterial Occlusive Diseases",
        "Coronary Artery Disease",
        "Coronary Disease",
        "Arteriosclerosis",
        "Heart Diseases",
        "Myocardial Ischemia",
        "Vascular Diseases",
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "PZ-128",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2016-05-27",
      "completion_date": "2019-09-17",
      "has_results": true,
      "last_update_posted_date": "2025-04-16",
      "last_synced_at": "2026-09-30T11:20:51.849Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Worcester, Massachusetts • Falls Church, Virginia",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Falls Church",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02561000"
    },
    {
      "nct_id": "NCT04421014",
      "title": "Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults 55 Years Old or Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metabolic Syndrome",
        "Normal Cognition"
      ],
      "interventions": [
        {
          "name": "Ketone Ester drink",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo: isocaloric dextrose drink",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2021-06-24",
      "completion_date": "2025-06-02",
      "has_results": true,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-09-30T11:20:51.849Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04421014"
    },
    {
      "nct_id": "NCT05232071",
      "title": "Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NASH - Nonalcoholic Steatohepatitis",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Lanifibranor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inventiva Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2022-06-29",
      "completion_date": "2024-06-04",
      "has_results": true,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-30T11:20:51.849Z",
      "location_count": 26,
      "location_summary": "Homewood, Alabama • Chandler, Arizona • Conway, Arkansas + 22 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Conway",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05232071"
    },
    {
      "nct_id": "NCT06758596",
      "title": "Research Investigating Drug Effects-2 (RiDE-2)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cannabis Use",
        "Substance Use Disorder (SUD)",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "THC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "18 Years to 21 Years"
      },
      "enrollment_count": 144,
      "start_date": "2026-07-15",
      "completion_date": "2031-06",
      "has_results": false,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-09-30T11:20:51.849Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06758596"
    },
    {
      "nct_id": "NCT02204813",
      "title": "To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bypass, Gastric",
        "Roux-en-Y Gastric Bypass",
        "Vertical Sleeve Gastrectomy",
        "Gastric Banding",
        "Bariatric Surgery"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lo-Xenin",
          "type": "DRUG"
        },
        {
          "name": "Hi-Xenin",
          "type": "DRUG"
        },
        {
          "name": "Extra Hi-Xenin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 13,
      "start_date": "2014-07",
      "completion_date": "2015-11-17",
      "has_results": false,
      "last_update_posted_date": "2018-04-27",
      "last_synced_at": "2026-09-30T11:20:51.849Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02204813"
    },
    {
      "nct_id": "NCT07458269",
      "title": "Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Ribupatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kailera",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 264,
      "start_date": "2026-03-04",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-09-30T11:20:51.849Z",
      "location_count": 35,
      "location_summary": "Mesa, Arizona • Sun City West, Arizona • Irvine, California + 31 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Sun City West",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Lake Forest",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07458269"
    },
    {
      "nct_id": "NCT06042153",
      "title": "DIALYSIS-TIR Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "End Stage Renal Disease on Dialysis"
      ],
      "interventions": [
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2023-12-05",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-09-30T11:20:51.849Z",
      "location_count": 5,
      "location_summary": "Chapel Hill, North Carolina • Dallas, Texas • Irving, Texas",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Irving",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06042153"
    }
  ]
}